# Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma

> **NCT06132438** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Charlotte Lemech** · enrollment: 26 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** PEP-CMV vaccine

## Key facts

- **NCT ID:** NCT06132438
- **Lead sponsor:** Charlotte Lemech
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11
- **Primary completion:** 2024-09
- **Final completion:** 2026-09
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2023-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06132438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06132438, "Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06132438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*